Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Leukemia 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Triple Negative Breast Neoplasms 1Stomatitis 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1Adenocarcinoma 1

Interventions

Rituximab 5Valganciclovir 3Zidovudine 2Methotrexate 2Leucovorin 2Doxorubicin 2merphos 1cc-486 1avelumab 1apatinib 1Vincristine 1Valacyclovir 1Vaccines 1Tomography, X-Ray Computed 1Prednisone 1Nivolumab 1Kidney Transplantation 1Interferons 1Hydroxyurea 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Etoposide 1Echocardiography 1EPOCH protocol 1Docetaxel 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Caves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Epstein-Barr Virus Infections × Valacyclovir × Clear all
NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

University of Minnesota

Phase 2 Completed
137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡